Kairos Pharma, LTD.·4

Nov 26, 6:50 PM ET

Murali Ramachandran 4

4 · Kairos Pharma, LTD. · Filed Nov 26, 2025

Insider Transaction Report

Form 4
Period: 2025-10-08
Murali Ramachandran
VP of Research and Development
Transactions
  • Award

    COMMON STOCK

    2025-10-08+152,672299,529 total
Footnotes (2)
  • [F1]Represents 152,672 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 152,672 RSUs are scheduled to vest in full on the first anniversary of the grant date.
  • [F2]Consists of (1) 142,191 shares of common stock and (2) 157,338 RSUs which remain subject to vesting.

Documents

1 file
  • 4
    ownership.xmlPrimary

    4